Iron Status and Restless Legs Syndrome in the Elderly

1994 ◽  
Vol 23 (3) ◽  
pp. 200-203 ◽  
Author(s):  
S. T. O'KEEFFE ◽  
K. GAVIN ◽  
J. N. LAVAN
1993 ◽  
Vol 69 (815) ◽  
pp. 701-703 ◽  
Author(s):  
S. T. O'Keeffe ◽  
J. Noel ◽  
J. N. Lavan

2013 ◽  
Vol 20 (1) ◽  
pp. 15-21 ◽  
Author(s):  
Eun Soo Kim ◽  
In-Young Yoon ◽  
Kukju Kweon ◽  
Hye Youn Park ◽  
Chung Suk Lee ◽  
...  

2009 ◽  
Vol 3 (4) ◽  
pp. 197-203 ◽  
Author(s):  
Pei-Hao Chen ◽  
Shih-Jung Cheng

2011 ◽  
Vol 12 (3) ◽  
pp. 295-301 ◽  
Author(s):  
Colin Quinn ◽  
Mateen Uzbeck ◽  
Imran Saleem ◽  
Paul Cotter ◽  
Javed Ali ◽  
...  

2017 ◽  
Vol 37 (04) ◽  
pp. 439-445 ◽  
Author(s):  
Barbara Felt ◽  
Tiffany Munzer

AbstractRestless legs syndrome (RLS) is a common and treatable neurologic condition in pediatric patients, with a prevalence as high as 2 to 3%. The diagnosis of RLS is made clinically based on an urge to move the legs accompanied by lower extremity discomfort that occurs during rest usually later in the day and is relieved by movement. Periodic limb movements in sleep (PLMS) can overlap with RLS, although PLMS also exists as a separate entity characterized by stereotyped movements of lower extremities in sleep. Both conditions may be highly debilitating and interfere with daily function notably in the areas of educational attainment and behavioral regulation. Iron deficiency has been implicated in the pathophysiology of both RLS and PLMS. Current evidence suggests that treatment of ferritin levels < 50 µg/L may be beneficial in improving pediatric RLS symptoms and comorbid conditions or daytime dysfunction associated with RLS. Areas for future research include (1) clarifying the ferritin or other iron status measure level which predicts iron treatment will provide symptom improvement in pediatric patients, and (2) randomized clinical trials using iron therapy to determine the degree and duration of treatment.


SLEEP ◽  
2020 ◽  
Author(s):  
Eric J Earley ◽  
Maria Didriksen ◽  
Bryan R Spencer ◽  
Joseph E Kiss ◽  
Christian Erikstrup ◽  
...  

Abstract Restless Legs Syndrome (RLS) is a common sensorimotor disorder, which can disrupt sleep and is thought to be caused in part by low cellular iron stores. Proton pump inhibitors (PPI) and histamine H2-receptor antagonists (H2A) are among the most commonly used drugs worldwide and show evidence of causing iron deficiency. We conducted a case/non-case observational study of blood donors in the U.S. (N=13,403; REDS-III) and Denmark (N=50,323; Danish Blood Donor Study, DBDS), both of which had complete blood count measures and a completed RLS assessment via the Cambridge Hopkins RLS questionnaire (CH-RLSq). After adjusting for age, sex, race, BMI, blood donation frequency, smoking, hormone use, and iron supplement use, PPI/H2A use was associated with RLS (Odds Ratio [OR] = 1.41; 95% confidence interval [CI], 1.13-1.76; P=0.002) in REDS-III for both PPI (OR = 1.43; CI, 1.03 – 1.95; P = 0.03) and H2A (OR = 1.56; CI, 1.10 – 2.16; P = 0.01). DBDS exhibited a similar association with PPIs/H2As (OR = 1.29; CI, 1.20 - 1.40; P &lt; 0.001), and for PPIs alone (OR = 1.27; CI, 1.17-1.38; P &lt; 0.001), but not H2As alone (OR = 1.18; CI, 0.92-1.53; P = 0.2). We found no evidence of blood iron stores mediating this association. The association of PPI, and possibly H2A, consumption with RLS independent of blood iron status and other factors which contribute to RLS risk suggest the need to re-evaluate use of PPI/H2A in populations at particular risk for RLS.


2018 ◽  
Vol 12 (8) ◽  
pp. 48-58
Author(s):  
Mehrdad Bastani ◽  
Gholamali Ghasemi ◽  
Morteza sadeghi ◽  
◽  
◽  
...  

Sign in / Sign up

Export Citation Format

Share Document